Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis (RopeRux in Myelofibrosis)
Key claim: A clinical trial is evaluating whether adding ropeginterferon alfa-2b to ongoing ruxolitinib therapy is safe and effective for patients with myelofibrosis.
Abstract
The purpose of this clinical trial is to learn if the study drug ropeginterferon alfa- 2b added to, standard of care, ruxolitinib is safe and effective in treating patients with Myelofibrosis.
Why this matters
Ropeginterferon alfa-2b is established in PV (and increasingly explored in ET) but has had limited prospective evaluation in myelofibrosis, where ruxolitinib remains the JAKi backbone yet is non-curative. Testing the JAKi + interferon combination specifically in PMF probes whether interferon’s putative clone-modifying activity can be safely layered onto ongoing JAK inhibition in a fibrotic, often cytopenic disease — a subtype-specific tolerability question that distinguishes PMF from PV/ET where interferon monotherapy is already feasible.